Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in severe reduced ejection fraction heart failure
ChiCTR2200055897Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: NT-proBNP. Started Apr 2021; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2200055897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055897.